CHART – Cancer and Haematology Academic Research Team

What we do

The Cancer & Haematology Academic Research Team  CHART - is a new clinical trials team working across Imperial College London and Imperial College Healthcare NHS Trust to deliver world class clinical trials of all phases at national and international levels.  Our trial managers work closely linked to the Imperial delivery team which allows for a more efficient and effective way of trial development.

We work with investigators from the initial stages of protocol development with the aim of producing well designed studies until the end of their delivery and archival.  We have robust quality assurance systems in place to ensure adherence to research governance standards, appropriate resources to provide adequate and stable infrastructure and senior staff to ensure expertise in the relevant disciplines.

As part of this work we will help to put together a competitive budget adhering to Imperial College London rules and regulations and supporting the delivery of the NHS team research work according to NIHR guidelines.

Our objective is to deliver studies within timelines and budget.

Why it is important

CHART has been created to meet the increasing demand for management and study support on investigator led academic trials and non-commercial externally sponsored studies. There is a range of studies that do not require full ICTU support which are still considered to be of strategic and financial importance to ICL and ICHNT.

Summary of current research

We specialise in cancer and haematology but have already ventured out onto other fields, ie. Surgery, Immunology and Inflammation, Metabolism Digestion and Reproduction amongst others as part of our portfolio.

Active trials:

• STARKAP | Study fo TSR-042 in the treatment of HIV-associated combination antiretroviral therapy (cART) refractory kaposi Sarcoma.
• PRIME | PRIME-HCC: Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC). 
• Precision HCC | Molecular markers to enable precision medicine in Hepatocellular Cancer.
• ProGREsS | Personalised Genetic Risk Estimates for Cancer Screening & Prevention. 
• ATB/Antibiotic ICPI | Qualification of antibiotic-induced gut perturbation as a therapeutically actionable driver of anti-cancer immunity. 
• Radiomics Panc | Development and validation of predictive and prognostic cancer biomarkers using Radiomics.
• On-Covid | OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic.
• HELP-ER | Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer.
• SSTR2 and lutetium/LANTANA | LANTana: Lutathera and ASTX727 in Neuroendocrine Tumours.
• FLiCIR | Fibrolamellar Hepatocellular Cancer Registry.
• GUMBIT | A pilot study to investigate the gut microbiome in patients with immune thrombocytopenia (ITP).
• PELICAN | A phase II study of etoposide-carboplatin (EP) chemotherapy in combination with pembrolizumab and lenvatinib maintenance in advanced high-grade neuroendocrine tumours (HG-NETs).
• RHEPaiR | Safety & efficacy of individualized dosing using the Holium platform in patients with unresectable Hepatocellular Cancer.
• NELMAS (NET with liver met) | Management of neuroendocrine liver metastases in adjuvant setting.
• (MRI scan to investigate microbleeds in Thrombocytopenic patients) | Can we detect subclinical brain micro haemorrhages in patients with thrombocytopenia using susceptibility sensitive MRI in order to better direct treatment.

Closed trials:

• JAKaL | A phase Ib study of INCB039110, a JAK1 inhibitor, in advanced hepatocellular carcinoma.
• PETAL | A Phase Ib Study of Pembrolizumab following Trans-Arterial Chemoembolization
  in Primary Liver Carcinoma MK3475-540.
• ArTisaN | A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs).
• Progem-2 | A Phase IB open label, dose-escalation study to assess the safety, pharmacokinetics and clinical activity of NUC-1031 given on days 1 & 8 with carboplatin on day 1, q3-weekly for 6 cycles in participants with recurrent ovarian cancer.
• Ovpsych2 | A randomised controlled trial to evaluate the impact of psychological support intervention after chemotherapy for women with ovarian cancer.
• Shortened hydration | A prospective study of tolerance comparing the current hydration regimen for the ABC02 chemotherapy regimen versus a shorter hydration protocol.
• AXMUS C | A phase II double blind, randomised controlled trial of vegf inhibitor axitinib monotherapy with early dynamic contrast enhanced ultrasound monitoring in chemorefractory third line metastatic colorectal cancer.
• MAGENTA | Metabonomic-genomic signature correlates of clinical resistance in metastatic colorectal cancer treated with anti-egfr therapy.
• Metabonomics | Metabonomics and Integrative Biology for Gynaecological Cancer
• PRIMAL | F-18 Fluoro-L-Thymidine PET for assessment of treatment Response to Immunotherapy Cancer: PRIMal study.
• TRUST | Trial on radical upfront surgery in advanced ovarian cancer.
• MATIS | Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS).